Diagnostic work up and staging in

carcinoma cervix

Dr. Samrat Dutta

Prof. S.C. Sharma, Prof. F.D. Patel REGIONAL CANCER CENTRE DEPTT. OF RADIO THERAPY PGIMER CHANDIGARH



Cervical Cancer Magnitude of the Problem: -V Cervical cancer is the SECOND most common cancer of women ✓ worldwide 500,000 new cases identified each year

INDIA

Commonest carcinoma in females
1.3 lakh/year



Transformation zone







Diagnosis of preinvasive stage

✓ CYTOLOGIC SCREENING
✓ VISUAL INSPECTION
✓ COLPOSCOPY
✓ BIOPSY
✓ ENDOCERVICAL CURRETTAGE





Sensitivity of PAP 51% FALSE NEG – 5-50% 20% LAB ERRORS









VISUAL INSPECTION METHOD

simple speculum examination

VISUAL INSPECTION WITH ACETIC ACID (VIA)



 \checkmark Acetic acid – malignant cells stain white

- Dissolves mucus
- Induces intracellular dehydration
- Causes coagulation of protein

Sensitivity and specificity of VIA - 70-92%



VISUAL INSPECTION LUGOLS IODINE

Iodine being glycophilic stains only the normal squamous epithelium-mahogany brown or black

Sensitivity 91.7% specificity 85.9%

Colposcopy



Colposcopy

Indications

Suspicious-looking cervix

Invasive carcinoma on cytology CIN 2 or CIN 3 on cytology Persisting (for more than 12-18 months) low-grade (CIN 1) abnormalities on cytology CIN 1 on cytology Persistently unsatisfactory quality on cytology Infection with oncogenic human papillomaviruses (HPV) Acetopositivity on visual inspection with acetic acid (VIA) Acetopositivity on visual inspection with acetic acid using magnification (VIAM) Positive on visual inspection with Lugol's iodine (VILI)



Colposcopy contd...



Magnification 16 times 4 main features colour changes Intensity of acetowhitening Marjins &contour Vascular features





Biopsy Colposocopy available suscpicious area

Punch Biopsy Or 4 quadrant biopsy Colposcopy Not available Employing Schiller's or Lugol's iodine



Ring biopsy from Squamocolumnar junction



Conisation (cone biopsy)

- ✓ When ?
- Unsatisfactory colposcopic findings
 - entire margins not visualised
- Inconsistent findings– colposcopy, cytology & directed biopsy
- ✓ Positve endocervical curettage
- ✓ To exclude gross invasive ca
- IT IS DIAGNOSTIC AS WELL AS THERAPEUTIC







MANDATORY after conisation
SPECIALLY IF referral cytology indicates a glandular lesion
If colposcopy unsatisfactory / not revealed any abnormality
as yield of ECC is very low neg ECC should not suggest absence of neoplasia







INV&SIVE C&RCINOM&



✓ 80 % Of lesions –ectocervix
Frank growth ---exophytic---friable, involves upper vagina
ulcerative---excavating cervix, vag fornices
infiltrative---endocervical growth

HISTOPATHOLOGY

90 % squamous cell carcinoma10 % adenocarcinoma



Clinical Presentation

Asymptomatic Bleeding P/V--- post coital / spotting intermenstrual postmenopausal discharge P /V ---Foul smelling PAIN-----pelvic/ hypogastric lumbosacral epigastric radiating to limbs Fatigue, weakness bladder & bowel complaints Symptoms of metastasis Uraemia Sepsis cachexia



Clinical examination

GENERAL SURVEY

pallor palpable neck nodes pedal edema B .P .

SYSTEMIC EXAMINATION

P/A--- tenderness, palpable lump, palpable liver,spleen CHEST auscultation

V LOCAL EXAMINATION

speculum inspection---- preferably Cusco's bivalve speculum digital palpation per vaginum bimanual palpation rectal examination

Local examination

∀ Speculum examination

red granular area on lips of cervix growth– size, proliferative,necrotic,

Y Per vaginal digital palpation

exact nature of growth	, friable	bleeds to touch,
infiltrative	proliferative,	
size of growth,	lips of cervix	involved
vaginal fornices,	walls of vagina	

V Bimanual examination

better reveals extent of growth to vagina, induration of bladder base felt through ant fornix in advanced cases

V Rectal examination

note involvement of parametrium--- soft or indurated

note whether *nodular*

extent to lateral pelvic wall rectal mucosal involvment





Cervical Carcinoma - Outcome

Host Factors

Anemia

Performance status (weight loss)

Age



INVESTIGATIONS

VI. ROUTINE / BASELINE INV

VII. DISEASE EXTENT

A.ENDOSCOPIC ASSESSMENT B.RADIOLOGIC STUDIES C.METASTATIC WORK UP

Routine investigations

1

HAEMOGRAM Hb, TLC DLC, PLATELETS Anaemia--blood loss nutritionally deprived depletion of fe stores in prolonged intermittent bleeding ---level of Hb affects prognosis ↓Hb→tumour oxygenation ↓ radioresistance[↑] **Biological aggressiveness, locoregional** recurrence

Optimal level-----11g/dl

Threshold for transfusion should be based on anaemia during treatment and not initial value



Renal function tests

∀ Urea

✓ Creatinine

serves as a baseline before starting treatment by cisplatin based chemoradiation

advanced diseases ureteric involovment,hydronephrosis ↑ urea, creatinine

Liver function tests baseline value elevated enzymes----indicates metastatic disease

Urine– routine &C/S baseline chek for absence of any UTI symptoms of dysuria, inreased frequency--- in advanced

stages

Chest X Ray assessment of cardiopulmonary status rule out any lung mets



Endoscopic assessment ∀85% cases presenting to us are in advanced cases ✓ Endoscopic assessment for bladder invasion rectal invasion **CYSTOSCOPY:-**Visualisation of only mucosa--nodularity frank growth ridges & furrows----submucosal involvment if they remain fixed to growth during palpation (i.e. P/V or P/R during cystoscopy) **bullous edema** as such does not indicate stage TV

Urinary malignant cytology

If cystoscopy not available urinary malignant cytology to detect bladder infiltration Overall specificity –93% 3 samples of urine specimen Anticoagulant not necessary Proctoscopy & sigmoidoscopy Indications–symp– tenesmus constipation along with bleeding P/R, diarrhoea clinical correlation- nodularity in P/R



Imaging for bladder & bowel For urinary tract- IVP For Bowel- barium enema &fistulography

INTRAVENOUS PYELOGRAM Indications- in all cases of stage II&above to detect ureter involvement extaluminal compression (? Enlarged paraaortic nodes) Hydroureteronephrosis **Displacement** of ureters





 Incidence of ureteral obstruction at diagnosis: 14 – 34.5% Sign of <u>advanced sidewall disease</u> or <u>bulky retroperitoneal adenopathy</u>





Low Tumor Burden

Upper vaginal disease Parametrial disease *Arthur et al IJROBP 31(4):1995

High Tumor Burden

Mid/distal vag disease Hydronephrosis Unilateral/bilateral sidewall disease



Cervical Carcinoma - Outcome

Tumor Variables

- Stage
- Tumor volume
- Parametrial/sidewall invasion
- Hydronephrosis
- Uterosacral ligament invasion

Staging of carcinoma cervix

 ✓ 1929- Radiologic subcommittee of Cancer Committee of the Health Organisation of the League of Nations began uniform staging of gynae cancers
 ✓ 1937- League of Nations classification for cervical cancer published
 ✓ 1958- staging by FIGO

FIGO staging

- Based on clinical evaluation (inspection, palpation, colposcopy), roentographic examination of chest, kidneys, and skeleton;
- endocervical curettage and biopsies

Endoscopic assessment by cystoscopy, proctoscopy, sigmoidoscopy IVP for imaging urinary tract and to detect any hydronephrotic changes due to obstruction of ureters

Because of the low yield of cystoscopy ,IVP, sigmoidoscopy, . and barium enema- patients with growth limited to cervix may forgo these procedures

With clinical evidence of more advanced disease ,however, cystoscopy and IVP are recommended in the pretreatment assessment.

Lymphangiograms USG, CT, MRI, are not used for clinical staging

	FIGO			
	Stage			
	0	Carcinoma in situ (preinvasive carcinoma)		
	Invasive	Invasive carcinoma		
STAGING	1	carcinoma confined to cervix (extension to corpus should be disregarded)		
Stage IAI	1a	Invasive carcinoma diagnosed only by microscopy.All gross lesions even with superficial invasion are stage 1B cancers. Invasion is limited to measured stromal invasion with maximum depth of 5.0 mm & no wider than 7.0 mm		
	1a ₁	Stromal invasion no greater than 3.00 mm in depth and 7.00 mm or less in horizontal spread.		
	1a ₂	Stromal invasion more than 3.0 mm and not more than 5.0 mm with horizontal spread 7.0mm or less		



- Stage IA1 previously (1985 FIGO revision) was defined as "minimal microscopically evident stromal invasion"
- ✓ and invasion of 5 mm or less in depth or 7 mm or less in horizontal spread as stage 1A2

depth	Pelvic node mets
<3mm	< 1 %
3-5 mm	1-8 %
> 5 mm	5-13 %

1995- FIGO revision -

1A1- invasion upto 3mm deep & 7 mm wide

1A2- invasion between 3 and 5 mm deep & 7 mm wide

	FIGO	
	stages	
3 cm	1B	Clinically visible lesion confined to the cervix or microscopic lesion greater than 1A2
	1B ₁	Clinically visible lesion 4.0cm or less in greatest dimension
Vaginal extension only	1B ₂	Clinically visible lesion more than 4 cm in greatest dimension
Paracervical	II	Tumor invades beyond cervix but not to pelvic wall or lower third of the vagina .
extension with or without vaginal involvement	II a	The carcinoma involves the vagina but not as far the lower third.
		Without parametrial invasion
	II b	Tumor invades beyond cervix with parametrial invasion but not upto pelvic wall

	FIGO		
	stages		
No extension polici wall	III	Tumour extends to pelvic wall . On rectal examination there is no cancer free space between the tumor and the pelvic wall . The tumour involves the lower third of vagina	
		All cases with a hydronephrosis or nonfunctioning kidney are included unless they are known to be due to other causes	
	IIIa	Tumor involves lower third of vagina no extension pelvic wall.	
	IIIb	Tumor extends to pelvic wall and/or causes hydronephrosis or non functioning kidney	



FIGO	
stages	
IV	Carcinoma extended beyond the true pelvis or has clinically involved the mucosa of the bladder or rectum.
IV a	Tumor invades mucosa of bladder or rectum or extends beyond true pelvis
IV b	Spread to distant organs

Notes about staging

The diagnosis of both stage 1A1 and 1A2 cases should be based on microscopic examination of removed tissues, **preferably a cone** ;which must include the entire lesion. The depth of lesion should not be more than 5.0 mm taken from the base of the epithelium ,either surface or glandular,from which it originates

The second dimension, the horizontal spread, must not exceed 7 mm. Vascular space involvement, either venous or lymphatic, should not alter staging but should be specifically recorded, as it may affect treatment decisions in the future. As a rule, it is impossible to estimate clinically whether a cancer of the cervix has extended to the corpus or not. Extension to the corpus should therefore be disregarded

A patient with a growth fixed to the pelvic wall by a short and indurated but not nodular parametrium should be alloted to stage IIB . It is impossible , at clinical examination, to decide whether a smooth and indurated parametrium is truly cancerous or only inflammatory. Therefore , the case should be placed in stage III only if the parametrium is nodular on the pelvic wall or if the growth itself extends to the pelvic wall



In case of doubt the lower stage is selected. After a clinical stage is assigned and treatment has been initiated the stage must not be changed because of subsequent findings by either extended clinical staging or surgical staging.



The presence of bullous oedema should not permit a case to be alloted to stage IV. Ridges & furrows into bladder wall – submucous invlovement of bladder if they remain fixed to growth at palpation during cystoscopy.

Malignant cytology of bladder washings need to be correlated with further examination & biopsy from bladder



Prognosis of patients depends on.....

✓ Early stage
 tumour size--- Depth of invasion
 lymphovascular invasion
 ✓ Advanced stage
 paraaortic & pelvic node
 Tumour size & extent of growth

age

size	Nodal mets	5 yr survival
<3 cm	22 %	84 %
>4 cm	36 %	66 %

depth	Pelvic	
	node mets	
<3mm	< 1 %	
3-5 mm	1-8 %	
> 5 mm	5-13 %	



stage	Pelvic node %	STAGE	Paraaortic node
I	11-18	IB- IIA	0-18%
		IIB	13-33%
II	32-45		
		III	46%
III	46-66		
		IVA	57%

Additional Radiology

Tumour volume Disease extentnodal spread parametrial & pelvic wall involvment

Lymphangiogram
Ultrasound
Computed tomograms
Magnetic resonance imaging
Positron emission tomogram





Primary goup

- ✓ Parametrial
- ✓ Paracervical
- ✓ Obturator
- ✓ hypogastric / internal iliac
- ∀ External iliac
- ∀ Sacral

Secondary group ✓ Common iliac

✓ Paraaortic







- **∀ Lymphatic trunks**
- 3 lateral trunks
 - upper---terminates in high internal iliac
 nodes
 branches to ext iliac &common iliac
 interrupted by paracervical nodes
 middle---originates near cardinal lig
 ----obturator node
 lower---presacral, inf gluteal , lower
 - **lower-**--presacral, inf gluteal, lower paraaortic nodes
- Anterior---follows bladder lymphatics to internal iliac nodes
- Posterior----follows uterosacral lig
- ---sup rectal, presacral, common iliac



 Interpretation of lymphangiogram based on examination of both – the lymphatic phase i.e. initial roentogram taken at completion of injection and the nodal phase – 24hr roentogram



Normal lymph node- has a granular pattern, oval or kidney shaped

Abnormal nodes- more rounded, may have a filling defect due to tumour deposition &irregularities along periphery of node



Bipedal lymphangiography used mainly to assess pelvic & paraaortic nodes

	sensitivity	specificity
pelvic	28%	100%
paraaortic	79%	

Even if nodes are not enlarged if architectural distortion+.....clue to metastasis- hence helpful in treatment planning

Disadv- peripheral goup of nodes- hypogastric, obturator,ext iliac not visualised Small metastatic lesions may not distort architecture

Sometimes gross metastatic tumour completely obliterate lymph nodes Long term follow up Not possible Allergy to drug, time consuming &cumbersome



ULTRASOUND ✓Ultrasound of abdomen & pelvis used to evaluate

tumour size invasion of parametrium pelvic side wall bladder & rectal invasion hydronephrotic changes metastasis lymph nodes (?) TRANSABDOMINAL TRANSVAGINAL TRANSRECTAL



CT SCAN

Value of CT scan in invasive Ca cervix ---assessment of advanced disease (stage>IIB) -- detection & biopsy of suspected lymph node metastasis --radiation treatment planning--contouring GTV, CTV, PTV, TV, IV

Magnetic Resonance Imaging

✓ Pelvic imaging like USG &CT scan – limited capability for tissue characterisation ✓ MRI superior soft tissue resolution-✓ Most effective in evaluating tumour volume endocervical lesions local extension lymph node status monitoring therapeutic response recurrent disease



MRI contd.....

Preservation of stromal ring – noninvasive cervical ca



Disruption of stromal ring– reliable sign of parametrial invasion



PET SCAN

PET --- functional test of glycolytic activity of tumour &relative deficiency of glucose 6 P in tumour cells
 MRI --- cannot image occult distant metastasis

Whole body PET can detect these occult mets---

	sensitvity	specificity	accuracy
Paraaortic	67 %	95%	88 %
pelvic	91 %	94 %	92 %

	sensitivity	Specificity
PET	88 %	92 %
CT	72 %	93 %
MRI	50 %	95 %
PET.CT	72 %	92 %



TNM staging

- Developed by Pierre Denoix 1943-1952 and 1st published in 1953
- Endorsed by American Joint Committee on Cancer (AJCC)
 - Tumour size (T) primary tumour that has not been previously treated
 - **Nodal involvement-** regional lymph nodes include paracervical, parametrial, hypogastric (obturator);
 - common , internal and external iliac; presacral and sacral nodes. Metastasis to lymph nodes outside the regional nodal group is classified as distant metastasis
- Metastatic involvement excludes peritoneal metastasis



STAGE GROUPING

Stage 0	Tis	No	M0
Stage IA	T1a	No	M0
Stage IA ₁	T1a ₁	No	M0
StageIA ₂	T1a ₂	No	M0
Stage 1B	T1b	No	M0
Stage 1B ₁	T1B ₁	No	M0
Stage 1B ₂	T1b ₁	No	M0
Stage IIA	T2a	No	M0
Stage IIB	T2b	No	M0
Stage IIIA	T3a	No	M0
Stage IIIB	T1,T2,T3a,T3b	N1	M0
Stage IVA	T4	Any N	M0
Stage IV B	Any T	Any N	M1



Hence TNM staging helps in estimation of prognosis and also planning therapy

Moreover TNM staging is a dual system

- clinical

 pathological (pT, pN ,pM) (postoperative histopathological)
 This also allows quality assurance of clinical staging



FIGO staging- should CT /MRI be incorporated?

- Management of cervical cancer is based on assessment of parametrial extension & nodal involvement
- Radical hysterectomy for medically fit Stage I patients or with minimal extension to proximal vagina (Stage IIA)
 - Radiation therapy for Stage IIB or greater
- FIGO staging takes into account tumour size but still does not include lymph node metastasis
- ✓ Errors of FIGO staging
 - stage IB---17-32% stage II- IV--- 67%



24.3% patients of stage IIIB present with hydronephrosis Excretory urography unnecessary when CT & MRI are used because of comparable accuracies of IVP,CT.MRI in detecting urinary obstruction

CT evaluation not only imp for detecting locoregional extent but also for radiation treatment planning



WHENCE.....CT /MRI may be preffered as primary diagnostic modality in ca cx V However.....sometimes overestimation of tumour size by MRI –19% CT & MRI may prove to be beneficial in clinically staged early disease by early detection of nodal metastasis & parametrial invasion ----treatment plan may change But in late/advanced staged disease no change of treatment option no benefit in overall survival



Moreover

✓ MRI costly, not universally available ✓ higher false positive rates of CT to detect parametrial invasion ✓ low diagnostic accuracy of CT 58% compared to clinical accuracy92% in detecting parametrial invasion \checkmark Lack of uniform quality in performing, interpreting CT & MRI **FIGO staging is still clinical** CT /MRI adds to diagnostic accuracy



Other investigations

Persistent levels 3 – 12 mo after T/T---failure

TUMOUR MARKERS CA125----- 21.5 % Adenoca CA19-9----32 % CEA PROG RECEPTORS + ----- ↑DFS ↓COX 2 LEVELS ----- better 5 yr survival c erb 2 ---- 49 % adenoca 38 % SCC



Role of sentinel node scintigraphy

- Sentinel node--- specific node that is 1st to receive drainage from malignancy & primary site for metastasis
- Presence or absence of metastatic disease in sentinel node reflects status of nodal basin as a whole
- V Lymphatic mapping of cervix--- 2 possible drainage sites
- ✓ Sensitivity
- 65%-- 87%
- ✓ Presently purely inv



✓ Phase III trials with survival end points necessary to establish its definite diagnostic role in ca cervix



CONCLUSIONS

Carcinoma of cervix is the leading cause of gynaecological cancers in INDIA

For invasive disease recommendations for diagnostic evaluation and treatment planning have evolved into 2 distinct processes--- clinical staging & extended clinical staging



Nodal metastasis & parametrial invasion are of paramount importance in treatment planning & prognosis

For stage I & IIA disease MRI &CT owing to satisfactory accuracy in evaluation of main prognostic factors ensures correct treatment planning

However >85% of cases presenting to us are > stage III hence still today diagnostic work up in carcinoma cervix is primarily clinical based on FIGO guidelines

